Bioactivity | Leniolisib (CDZ173) phosphate is a potent and selective PI3Kδ inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment. |
Invitro | APDS 突变体 p110δ 在细胞系和患者来源的淋巴细胞中的表达导致通路活性增加,以 AKT 或 S6 的磷酸化来衡量。而 Leniolisib phosphate 以浓度依赖性方式抑制该通路活性[1]。 |
Name | Leniolisib phosphate |
CAS | 1354691-97-6 |
Formula | C21H28F3N6O6P |
Molar Mass | 548.45 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406 [2]. Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8(9):975-980. |